# Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer

> **NCT05367440** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **AstraZeneca** · enrollment: 174 (actual)

## Conditions studied

- Metastatic Prostate Cancer

## Interventions

- **DRUG:** AZD5305
- **DRUG:** Enzalutamide
- **DRUG:** Abiraterone Acetate
- **DRUG:** Darolutamide
- **DRUG:** Apalutamide

## Key facts

- **NCT ID:** NCT05367440
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-06-02
- **Primary completion:** 2031-04-11
- **Final completion:** 2031-04-11
- **Target enrollment:** 174 (ACTUAL)
- **Last updated:** 2025-12-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05367440

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05367440, "Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05367440. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*